We are international
Donate
• myeloma tv TEXT SIZE   
webcasts from medical meetings    back

A. Palumbo, MD, The Italian Multilple Myeloma Study Group
06.09.04
Dr. Palumbo's poster presented results of a study looking at oral melphalan, prednisone, and thalidomide (MPT) for newly diagnosed myeloma patients.






 related articles
REVLIMID®/THALOMID® TIP CARD
Celgene's Patient Support Coordinator Program
THALOMID®
Open Thalomid® (thalidomide) Trials
Fast Track for First Prescription™
Celgene's Patient Support Coordinator Program
Understanding Thalidomide Therapy
IMF "Ask the Expert" Videos: Thalidomide
Thalidomide Approval in Europe Could Provide Survival Benefits to Newly Diagnosed Myeloma Patients
NEW THALIDOMIDE DATA CONFIRMS SURVIVAL BENEFITS FOR OLDER PATIENTS
Blood Cancer Breakthroughs Presented at ASCO 2006
Confusing news stories about the efficacy of thalidomide. What does this all mean?
Don’t be misled by news reports that say thalidomide stops working for myeloma patients.


You might also be interested in:

General Information
REVLIMID®/THALOMID® TIP CARD
This handy tip card includes indications, dosage, and potential side effects.

Celgene's Patient Support Coordinator Program
Celgene's Patient Support Coordinators assist patients and healthcare providers to navigate the challenges of reimbursement, provide information about co-pay assistance, and answer general questions about Revlimid.

THALOMID®
Celgene's website for Thalomid® with information on clinical information, prescribing guidelines, benefits and risks, etc.

Clinical Trials
Open Thalomid® (thalidomide) Trials

Patient Assistance
Fast Track for First Prescription™
Celgene has developed a new program called Fast Track for First Prescription™ to help eligible patients receive their first prescriptions for a Celgene product quickly and efficiently.

Celgene's Patient Support Coordinator Program
Celgene's Patient Support Coordinators assist patients and healthcare providers to navigate the challenges of reimbursement, provide information about co-pay assistance, and answer general questions about Revlimid.

Publications
Understanding Thalidomide Therapy
Using thalidomide to treat myeloma is a new idea, but thalidomide itself has been studied for many decades. This provides a basic understanding of thalidomide therapy.

Videos
IMF "Ask the Expert" Videos: Thalidomide
We asked the experts about thalidomide alone and in trials with various other agents--response, side effects, and the impact of FDA approval on its use in myeloma. Our "Ask the Expert" Videos are a new feature of our expanded website.

News
Thalidomide Approval in Europe Could Provide Survival Benefits to Newly Diagnosed Myeloma Patients
The European Commission Grants Marketing Authority for Melphalan-Prednisone-Thalidomide Regimen

NEW THALIDOMIDE DATA CONFIRMS SURVIVAL BENEFITS FOR OLDER PATIENTS
Findings Could Support Marketing Authorization for thalidomide in Europe

Blood Cancer Breakthroughs Presented at ASCO 2006
Breakthroughs in the treatment of blood cancer were presented at the American Society of Clinical Oncology (ASCO) meeting in Atlanta. In one of the findings, Thalomid®, when used in the treatment of newly diagnosed elderly patients with the disease, was found to be more effective than stem cell transplants. This once dangerous drug is now bringing new hope to a new generation of patients. Video featuring patients Hardy Jones and Paul Nicholss and the IMF's Dr. Brian Durie.

Confusing news stories about the efficacy of thalidomide. What does this all mean?
Thalidomide has been used since 1997 in the treatment of myeloma. Remarkable efficacy has been observed both alone and in combination with dexamethasone and other drugs. Strangely, only recently have comparative trials been completed to show the clear added benefit of thalidomide and the drug still awaits formal FDA approval for myeloma treatment. Two recent studies have lead to some confusion about thalidomide efficacy.

Don’t be misled by news reports that say thalidomide stops working for myeloma patients.
The news report must be viewed within the context of a complex study, and within the context of newer, more positive experience with thalidomide...